Fiera Capital Corp Purchases 13,826 Shares of AstraZeneca plc (NYSE:AZN)

Fiera Capital Corp grew its stake in shares of AstraZeneca plc (NYSE:AZN) by 33.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 54,668 shares of the company’s stock after acquiring an additional 13,826 shares during the period. Fiera Capital Corp’s holdings in AstraZeneca were worth $2,442,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Clear Harbor Asset Management LLC bought a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $25,000. Verus Capital Partners LLC bought a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $27,000. Patriot Financial Group Insurance Agency LLC raised its stake in shares of AstraZeneca by 223.8% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 557 shares of the company’s stock valued at $25,000 after acquiring an additional 385 shares in the last quarter. OmniStar Financial Group Inc. bought a new stake in shares of AstraZeneca during the first quarter valued at approximately $26,000. Finally, Golden State Wealth Management LLC bought a new stake in shares of AstraZeneca during the first quarter valued at approximately $31,000. 17.11% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE:AZN opened at $55.22 on Friday. The company has a market capitalization of $145.08 billion, a price-to-earnings ratio of 93.59, a price-to-earnings-growth ratio of 1.68 and a beta of 0.56. AstraZeneca plc has a 52 week low of $36.15 and a 52 week high of $57.44. The company has a quick ratio of 0.57, a current ratio of 0.75 and a debt-to-equity ratio of 1.32. The firm has a 50 day moving average of $50.01 and a 200 day moving average of $48.29.

AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.06. AstraZeneca had a net margin of 5.94% and a return on equity of 33.97%. The business had revenue of $6.35 billion for the quarter, compared to analyst estimates of $5.95 billion. During the same period in the previous year, the company earned $0.89 earnings per share. The business’s revenue for the quarter was up 16.3% on a year-over-year basis. On average, sell-side analysts expect that AstraZeneca plc will post 2.01 EPS for the current year.

Several research firms have recently weighed in on AZN. Morgan Stanley reaffirmed an “equal weight” rating on shares of AstraZeneca in a research note on Wednesday, May 6th. ValuEngine raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, February 4th. Argus boosted their price objective on shares of AstraZeneca from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Guggenheim reissued a “buy” rating on shares of AstraZeneca in a research note on Friday, May 1st. Finally, Cowen reissued a “buy” rating and issued a $55.00 price objective on shares of AstraZeneca in a research note on Friday, February 28th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $54.67.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: What does a bar chart display?

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.